Curated registry of Phase 3 AD clinical trials with their outcomes, mechanism, and (for failures) the most likely contributing factors. Initial v1 set focuses on landmark anti-amyloid and secretase trials plus the symptomatic standards of care; subsequent commits should add tau-targeted trials, anti-inflammatory trials, lifestyle / multidomain trials, and the prevention trials in cognitively normal at-risk populations.